Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969802 | 0.84 | AHCY (1.00) | AHCY | |
| SCHEMBL2019337 | 0.84 | AHCY (1.00) | AHCY | |
| SCHEMBL12573420 | 0.78 | AHCY (0.81) | AHCY | |
| SCHEMBL2021711 | 0.76 | AHCY (1.00) | AHCY | |
| SCHEMBL16463597 | 0.75 | AHCY (0.71) | AHCY | |
| SCHEMBL2022388 | 0.75 | AHCY (0.71) | AHCY | |
| SCHEMBL1969057 | 0.75 | AHCY (0.71) | AHCY | |
| SCHEMBL2421602 | 0.75 | AHCY (1.00) | AHCY | |
| SCHEMBL10459031 | 0.75 | AHCY (1.00) | AHCY | |
| SCHEMBL10432751 | 0.75 | AHCY (1.00) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| WO-2010027935-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | AHCY, AHCYL1, BHMT | AHCY 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.